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Abstract 
Several promising therapies assessed in the adult critically ill in large, multicenter randomized controlled trials (RCTs) 
were associated with significantly increased mortality in the intervention arms. Our hypothesis was that there would 
be wide ranges in sponsorship (industry or not), type(s) of intervention(s), use of DSMBs, presence of interim analy-
ses and early stopping rules, absolute risk increase (ARI), and whether or not adequate prior proof-of-principle Phase 
II studies were done of RCTs that found increased mortality rates of the intervention compared to control groups. 
We reviewed RCTs that showed a statistically significant increased mortality rate in the intervention compared to 
control group(s). We recorded source of sponsorship, sample sizes, types of interventions, mortality rates, ARI (as well 
as odds ratios, relative risks and number needed to harm), whether there were pre-specified interim analyses and 
early stopping rules, and whether or not there were prior proof-of-principle (also known as Phase II) RCTs. Ten RCTs 
(four industry sponsored) of many interventions (high oxygen delivery, diaspirin cross-linked hemoglobin, growth 
hormone, methylprednisolone, hetastarch, high-frequency oscillation ventilation, intensive insulin, NOS inhibition, 
and beta-2 adrenergic agonist, TNF-α receptor) included 19,126 patients and were associated with wide ranges of 
intervention versus control group mortality rates (25.7–59 %, mean 29.9 vs 17–49 %, mean 25 %, respectively) yielding 
ARIs of 2.6–29 % (mean 5 %). All but two RCTs had pre-specified interim analyses, and seven RCTs were stopped early. 
All RCTs were preceded by published proof-of-principle RCT(s), two by the same group. Seven interventions (except 
diaspirin cross-linked hemoglobin and the NOS inhibitor) were available for use clinically at the time of the pivotal 
RCT. Common, clinically available interventions used in the critically ill were associated with increased mortality in 
large, pivotal RCTs even though safety was often addressed by interim analyses and early stopping rules.
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Background
In Critical Care Medicine (CCM), randomized controlled 
trials (RCTs) are the best evidence to determine whether 
novel drugs, devices and clinically available therapies are 
effective [1, 2], safe, superior to “conventional” thera-
pies and recommended for clinical use [3]. We use the 
term “conventional” to refer to therapies and not to pla-
cebo. The Surviving Sepsis Campaign guidelines put a 
premium on RCTs [3]. “Positive” (i.e., statistically signifi-
cant) RCTs are sometimes judged as closer to “truth” [2, 
4] because some negative RCTs are underpowered.
RCTs must be closely monitored by independent Steer-
ing Committees and Data Safety Monitoring Boards 
(DSMB) complemented by interim analyses and early 
stopping rules [5]. Superiority design RCTs are done 
because of prior clinical equipoise, and test the hypoth-
esis that the new intervention is superior to the conven-
tional intervention but use two-sided statistical testing 
to determine whether either the new or conventional 
intervention is statistically superior. Thus, new therapy 
must have clinical equipoise to satisfy ethical concerns 
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[6, 7] and to justify the resources (trial subjects, human 
staff and financial resources) required. Sometimes, piv-
otal RCTs were associated with statistically significantly 
increased mortality with the new intervention [8–13].
Recent reviews consider why so many RCTs in adult 
sepsis [4] and critical care [2] are not positive, but the 
subject of excess mortality associated with the interven-
tion group has not been thoroughly reviewed recently. 
Our hypothesis was that there would be wide ranges in 
sponsorship (industry or not), type(s) of intervention(s), 
use of DSMBs, presence of interim analyses and early 
stopping rules, absolute risk increase (ARI), and whether 
or not adequate prior proof-of-principle Phase II studies 
were done of RCTs that found increased mortality rates 
of the intervention compared to control groups.
Methods
RCT selection criteria, inclusion criteria and characteristics 
of RCTs
We searched published literature for adult critical care 
RCTs powered for mortality as the primary endpoint 
that showed statistically significantly increased mortal-
ity in the intervention group compared to the control 
(“conventional”) group(s). We used “trial,” “sepsis,” “criti-
cal illness,” “critically ill,” “acute lung injury” and “acute 
respiratory distress syndrome” key terms. We recorded 
source of sponsorship, geographical settings, sam-
ple sizes, randomization, blinding interventions used, 
absolute mortality rates, absolute risk increase (ARI), 
odds ratios, relative risks and number needed to harm, 
whether or not each RCT had a DSMB, pre-specified 
interim analyses, whether or not there were pre-spec-
ified stopping rules, and whether or not each RCT was 
stopped early. We also determined whether or not there 
were prior proof-of-principle RCTs relevant to each RCT 




We found ten adult critical care-related RCTs that were 
designed and powered for mortality that showed signifi-
cant increased mortality rates in the intervention com-
pared to the control group(s) (Table 1).
Sponsorship and geographical settings
Of the ten RCTs, four were industry sponsored [11, 13–
15] and six [8–10, 12, 16, 17] were supported by peer 
review granting agencies or by academic institutions. The 
geographical settings were truly global, ranging from sin-
gle country (USA or Canada only), to regions (Scandina-
via), to multicontinent (Asia, EU and North America).
Conditions studied
There was a wide range of conditions studied including 
ALI/ARDS [9, 16] (two RCTs), critically ill [8, 10, 13] 
(three), severe sepsis [12] (one), head injury [17] (one), 
hemorrhagic shock [14] (one) and septic shock [11, 15] 
(two).
Interventions
The RCTs assessed a very wide range of interventions 
including high oxygen delivery [10], beta-2 adrener-
gic agonist [9], diaspirin cross-linked hemoglobin [14], 
human growth hormone [13], methylprednisolone 
[17], hetastarch [12], high-frequency oscillation venti-
lation [16], intensive insulin [8], nitric oxide synthase 
(NOS) [11] inhibitor and TNF-α receptor [15] (Table 1). 
Table 1 Subjects, industry sponsorship, geographical settings and  interventions tested in  adult critical care RCTs 
with increased mortality in intervention groups
DO2 oxygen delivery, NS normal saline, iNOS inducible nitric oxide synthase, IV intravenous, ARDS acute respiratory distress syndrome
References Subjects of RCT Industry  
sponsored?
Geographical setting Intervention group Control group
Hayes [10] Critically ill No UK High DO2 Normal DO2
Fisher [15] Septic shock Yes USA TNF-α receptor Placebo
Sloan [14] Hemorrhagic shock Yes USA Diaspirin-hemoglobin Normal saline
Takala [13] Critically ill Yes EU Growth hormone Placebo
Edwards [17] Head injury No UK Methylprednisolone Placebo
Perner [12] Severe sepsis No Scandinavia Hetastarch (HES130/0.42) Ringers lactate
Ferguson [16] ARDS No Canada High-frequency oscillation Control ventilation strategy 
targeting lung recruitment
Finfer [8] Critically ill No Australia/New Zealand/
Canada
Intensive insulin Normal insulin
Lopez [11] Septic shock Yes EU/North America iNOS inhibitor (546C88) Placebo
Gao Smith [9] ALI/ARDS No USA IV salbutamol Placebo
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Remarkably, seven of ten interventions (all except diaspi-
rin cross-linked hemoglobin, the particular NOS inhibi-
tor and TNF-α receptor) were available for use clinically 
at the time of the pivotal RCT.
Sample sizes, randomization and blinding
The sample sizes of RCTs also ranged widely from 98 to 
10,008 for a total of 19,126 patients (Table  2). Nine of 
ten RCTs had two groups (intervention and control) that 
were randomized 1:1. One study was more complex. The 
trial of human growth hormone [13] was composed of 
two concurrent RCTs, one a multicenter RCT in Finland 
and the other a multicenter RCT in many countries; both 
RCTs randomized patients 1:1 to human growth hor-
mone or placebo.
Randomization was blinded in all RCTs. The inter-
ventions were blinded in RCTs of diaspirin cross-linked 
hemoglobin versus normal saline [14], human growth 
hormone versus placebo [13], methylprednisolone ver-
sus placebo [17], hetastarch versus crystalloid [12], nitric 
oxide synthase (NOS) [11] inhibitor versus placebo, sal-
butamol versus placebo [9] and TNF-α receptor versus 
placebo [15].
Mortality rates, odds ratios, relative risks and absolute risk 
increases (ARIs)
The primary results showed very wide ranges of interven-
tion and control mortality rates (intervention arms: 25.7–
59  %, mean 29.9  %, versus control arms: 17–49  %, mean 
25 %) (Table 2; Fig. 1). The number of deaths in intervention 
groups exceeded the number of deaths in control groups 
by 514 (Table 2). The odds ratio was reported in only one 
RCT [8] (odds ratio 1.14 for increased mortality). The rela-
tive risks ranged from 1.17 to 2.4 (Table  2). The absolute 
risk increases (ARIs) ranged widely from 2.6 to 29 % (mean 
13  %) such that the number needed to harm also ranged 
widely from 3.5 to 38.5 (mean 20) (Table 2; Fig. 2).
Causes of increased mortality: possible off‑target effects
Most of the RCTs had secondary findings that might 
explain the increased mortality rates of the intervention 
compared to the control groups. Hayes and colleagues 
[10] assessed increased oxygen delivery; the interven-
tion group had higher doses of dobutamine that were 
associated with increased risk of tachyarrhythmias—
that could have increased mortality. Gao Smith et  al. 
[9] assessed intravenous salbutamol infusion and found 
Table 2 Sample sizes, mortality rates, absolute risk increases and  number needed to  harm (NNH) in  adult critical care 
RCTs showing increased mortality in the intervention groups
Four-week mortality rates of albumin versus control groups
In Fisher [15] RCT TNF-α receptor, the primary analysis was a trend test of placebo and increasing doses of TNF-α receptor. Mortality rates are shown for the dose 
groups and then for the combined intervention versus control groups (45/30)










P value Absolute risk 
increases (%)
NNH
Hayes [10] 100 (50/50) 27/17
54/34 %
10 0.04 20 5
Fisher [15] 141 (108/33) 59/10
30/48/53/33 %a
(45/30)
49 0.02 15 6.6
Sloan [14] 98 (52/46) 24/8
46/17 %
16 0.03 29 3.5
Takala [13]a 280 (119/123) 46/24
39/20 %
22 <0.001 19 5.3
Edwards [17] 10,008 (5007/5001) 1248/1075a
25.7/22.3 %
173 0.0001 5 20
Perner [12] 798 (398/400) 203/172
51/43 %
31 0.03 8 12.5
Ferguson [16] 548 (275/273) 129/96
47/35 %
33 0.005 12 8.3
Finfer [8] 6030 (3016/3014) 829/750
27.5/24.9 %
79 0.02 2.6 38.5
Lopez [11] 797 (439/358) 259/175
59/49 %
84 <0.001 10 10
Gao Smith [9] 326 (162/164) 55/38
34/23 %
17 0.02 11 9
Totals or means 19,126 (9626/9462) 2879/2365
29.9/25 %
514 5 20
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more tachyarrhythmias in the intervention than the con-
trol arm. NOS inhibition was associated with increased 
cardiovascular mortality perhaps because of decreased 
cardiac index [11] in the NOS inhibitor intervention 
versus control group. Hetastarch causes increased renal 
toxicity [acute kidney injury (AKI)], and AKI might 
have increased mortality [18]. HFOV [16] might have 
decreased venous return, increased the use of vasodilat-
ing sedative agents or increased barotraumas compared 
to control ventilation. Intensive insulin was associated 
with increased risk of severe hypoglycemia that might 
explain increased mortality of intensive versus usual 
insulin [8]. Diaspirin-hemoglobin has vasopressor 
effects, and the authors speculated that diaspirin-hemo-
globin could have increased hemorrhage compared to 
placebo [14]. However, increased hemorrhage was not 
documented; we suggest that it is more likely that the 
vasopressor effects resulted in patients appearing sta-
bilized when they were not. It was hypothesized that 
removal of TNF-α by TNF-α receptor could have been 
deleterious [15]. The cause of excess mortality associated 
with use of human growth hormone was not explained, 
but the authors speculated mechanisms [13]. There were 
no “off-target” unexpected complications identified in 
the primary publications of any of these RCT that could 
have explained the excess mortality of the intervention 
arms.
Interim analyses and early stopping rules
According to the available published information, all but 
two [10, 15] of the RCTs had independent DSMBs with 
pre-specified interim analyses and prospectively defined 
early stopping rules (Table  3). Interestingly, one of the 
RCTs [10] that had no independent DSMB was the old-
est RCT we examined, from an era when interim analy-
ses and early stopping rules were not commonly used. 
Of note, eight of ten RCTs were stopped early due to 
potential harm (i.e., increased mortality rate) in the inter-
vention arm (Table 3).
Prior proof‑of‑principle RCTs
All but one of the RCTs was preceded by prior proof-of-
principle (Phase II) RCTs, and one RCT [8] was preceded 
by a similar RCT of intensive insulin in the critically ill 
[19]. One RCT was the first treatment with TNF-α recep-
tor in septic shock [15]. However, according to the pri-
mary publication, only two RCTs were preceded by a 
proof-of-principle RCT by the same group as the pivotal 
RCT [11, 16].
Discussion
We found a relatively small number of RCTs in adult 
CCM that showed that the new intervention was associ-
ated with increased mortality compared to control group. 
Most RCTs were academically sponsored and assessed a 
wide range of nearly always clinically available interven-
tions. The intervention harm signal was remarkably wide: 
Absolute risk increase ranged from 2.6 to 29  % (mean 
5  %), and the number needed to harm ranged from 3.5 
to 38.5 (mean 20). The risks of RCTs finding significantly 
increased mortality were not explained by the source of 
sponsorship, geographical settings, lack of blinding, lack 
of DSMBs or early stopping rules, underlying conditions, 
inclusion criteria (which ranged widely) or the types of 
interventions (which also ranged widely). Few prior POP/
Phase II RCTs of the particular intervention were done by 
the same group doing the pivotal/Phase III RCT. While 
eight of ten RCTs did interim analyses and seven were 
stopped early, none of the RCTs used response adaptive 
RCT design.
Ironically these large, pivotal RCTs moved forward 
because prior proof-of-principle (POP)/Phase II RCTs 
showed significant results for a surrogate marker cho-











Fig. 1 Intervention and control group mortality rates of adult critical 
care RCTs that found increased mortality of the intervention com-













Fig. 2 Absolute increased risk of death rates (ARIs) and number 
needed to harm (NNH) of adult critical care RCTs that found increased 
mortality of the intervention compared to control group(s)
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the POP RCTs were false-positive signals of success of 
pivotal/Phase III RCTs. The reasons for these false-pos-
itive signals could include inadequate surrogate mark-
ers, changes in dose, changes in usual care, changes in 
inclusion criteria and settings and/or the play of chance 
between the POP/Phase II and pivotal/Phase III RCTs. 
These examples of increased mortality rates of the inter-
vention compared to control groups in pivotal/Phase 
III RCTs after prior positive POP/Phase II highlight the 
need for more accurate surrogate markers—biomarker(s) 
and/or clinical markers—that predict success in pivotal/
Phase II RCTs.
We have extended the prior review of increased mortal-
ity trials by Freeman et al. [20] who reviewed only human 
growth hormone, the NO inhibitor L-NMA and diaspi-
rin-hemoglobin. Furthermore, Freeman and colleagues 
[20] concluded that “factors in the design and conduct 
of the clinical trial that led to this result be thoroughly 
discussed.” Ospina-Tascon et  al. [21] reviewed methods 
and quality of multicenter RCTs that had mortality as a 
primary endpoint and found seven trials as of 2008 that 
found increased mortality in the intervention group; they 
concluded that relatively few RCTs “show a beneficial 
impact of the intervention on the survival of critically ill 
patients.” We have added to Ospina-Tascon et al. [21] by 
focusing on RCTs showing harm, and we have updated 
RCTs reported since 2008. The small number of RCTs 
in CCM, rigorous Data and Safety Monitoring Board 
processes, and/or robust proof-of-concept RCTs could 
explain the low number of harmful RCTs in CCM.
The interventions ranged widely and were nearly 
always clinically available, suggesting that adult CCM 
adapted new technologies without positive pivotal RCTs. 
Clinically available interventions included human growth 
hormone, methylprednisolone [17], increased oxygen 
delivery [10], novel resuscitation fluid for resuscitation 
[12], high-frequency oscillation ventilation [16] and sal-
butamol. There were three interventions that were not 
available clinically: diaspirin cross-linked hemoglobin 
[14], NO synthase (iNOS) inhibitor L-NMA [11] and 
TNF-α receptor [15].
An alternative interpretation is that the new interven-
tions were unproven, that only large pivotal Phase III 
RCTs powered for mortality would prove efficacy, and 
that inevitably some interventions increase mortality in 
Phase III. Thus, some argue such RCTs are necessary—
indeed critical—to guide clinical practice away from 
harmful interventions.
Finding increased mortality of the “conventional” 
group is essentially showing that the newer therapy is 
Table 3 Frequency and statistical analyses of interim analyses, early stopping and prior Phase II RCTs in adult critical care 
RCTs showing increased mortality in the intervention groups
Two parallel RCTs in Finland and in Europe (UK, the Netherlands, Belgium and Sweden) are reported together [13]. Because of slow recruitment due to the 
unexpectedly high incidence of exclusion criteria, the design was changed before the first interim analysis. The revised design was a fixed-sample analysis of 170 and 
190 patients in the Finnish and multinational studies
D/C’d discontinued, NA not available in primary publication
a The interim analyses methods were not stated. The primary analysis was log rank to 28 days
b Prior to the NICE SUGAR RCT [8], van den Berghe et al. [19] had published a similar RCT of intensive versus conventional insulin treatment in critically ill patients
c Prior small RCTs in burns, postoperative surgical patients, trauma, sepsis and critically ill non-septic patients
d Many prior small RCTs in head injury
e Several prior RCTs in septic shock, high-risk surgical, trauma and critically ill patients
f Several prior RCTs in trauma and critically ill patients
g Several prior trials of intensive insulin
References Interim analyses (frequency) Interim statistical test RCT D/C’d early Prior Phase II RCT (n) DSMB
Hayes [10] Yes (every 50 patients) Chi-square Yes Yese No
Fisher [15] No NA No No Not stated
Sloan [14] Yes (after 10, 25, 50 and 75 %  
enrollment)
Possibly Log rank 28 daya Yes Yesf Yes
Takala [13]g Yes (group sequential trials; 150 then 
every 40 patients)
Chi-square Yes Yesc Yes
Edwardsd [17] Annually Chi-square Yes Yes$ Yes
Perner [12] Yes (after 400 patients) Chi-square No Yes Yes
Ferguson [16] Yes (pilot phase after 94, 300, 500 and 
700 for safety, 800 for efficacy)
Mantel–Haentszel Chi-square Yes Yes (N = 25) Yes
Finfer [8]b Yes (after 1500 and 4000 patients) Chi-square No Yesg Yes
Lopez [11] Yes Triangular test with Christmas tree cor-
rection at stopping boundaries
Yes Yes (n = 312) Yes
Gao Smith [9] Yes (every 12 months) 95 % CI Yes Yes (n = 40) Yes
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more effective and that is the goal of the vast majority 
of superiority design RCTs in critical care. We chose to 
search for and review papers in which the results were 
the opposite of the initial hypothesis—i.e., the “conven-
tional” intervention was superior, and the new therapy 
significantly increased mortality. Our contention is the 
same regardless of design, i.e., we aim to minimize harm 
from new interventions in future RCTs. If more patients 
die with the conventional therapy, that is the same as 
showing that the new therapy is more effective. We thus 
believe it does matter whether the increased mortality is 
in the “conventional” therapy group (i.e., showing more 
benefit with the new intervention) versus in the new 
therapy group (i.e., the hypothesis that the new interven-
tion was better is not merely not shown, and the exact 
opposite to the hypothesis is shown). We did not avoid 
RCTs in which there are contrasting strategies in which 
none can be considered as “new” or “conventional.”
Equipoise is a crucial issue for our study of RCTs show-
ing increased mortality with the new intervention. One 
might consider that if there was equipoise regarding 
interventions prior to RCTs (and there must be equipoise 
for ethical conduct and ethics approval of RCTs), then 
one might suppose that there would have been a simi-
lar number of RCTs showing increased mortality with 
the new intervention as the number of RCTs showing 
increased mortality with the “conventional” intervention. 
It is possible that RCTs that showed increased mortal-
ity with the “conventional” intervention are much more 
numerous than the inverse; however, the low number of 
RCTs in CCM—sepsis in particular—that found signifi-
cantly lower mortality with the new intervention suggests 
that it is not the case that RCTs that showed increased 
mortality with the “conventional” intervention are much 
more numerous than the inverse.
It is also possible that harmful effects of interven-
tions are more easily identified than beneficial effects, 
for example, in a subgroup. In a hypothetical placebo-
controlled study of penicillin in sepsis, where beneficial 
effects in a small subgroup of patients would be difficult 
to prove, anaphylactic reactions would be well recog-
nized. This heterogeneity of treatment effect in detection 
of benefit versus harm was reviewed elegantly in simula-
tions of sepsis RCTs by Iwashyna et  al. [22]. They show 
that positive RCTs (i.e., beneficial overall) could have 
buried in them subgroup(s) with consistent harm or lit-
tle benefit such as low-risk patients who met enrollment 
criteria.
It is possible that some RCTs that found increased 
mortality with the “new intervention” were not published 
(especially before clinicaltrials.gov registration). If the 
following supposition were true—there were the same 
number of RCTs in which both new and old intervention 
increased mortality—then that supposition would indi-
cate that the vast majority of RCTs were unable to show 
anything other than equivalence, or non-inferiority.
Response adaptive trial design might decrease the risk 
of RCTs that show increased mortality of intervention 
versus control group(s). Response adaptive trial design 
RCTs adjust group randomization (intervention or con-
trol) and sometimes dose while the RCT progresses by 
using ongoing interim results. This is scientifically sound 
when the algorithms for group/dose assignment are com-
prehensively pre-specified and investigators and spon-
sors cannot adjust ongoing randomization. Strengths 
of response adaptive trial design include more efficient 
assessment of efficacy, limited risk of RCTs that find 
potential harm (by decreasing the sample size compared 
to frequentist statistical trial design), decreased time and 
expense (i.e., more efficient futility rules), improved drug 
dose selection and earlier completion of negative RCTs. 
We do acknowledge that this approach could limit the 
enrollment of a sufficient number of patients to be highly 
confident about mortality differences.
Response adaptive trial design often adjusts sample size 
to prevent an underpowered RCTs or excessively large 
RCTs when the treatment effect is larger than expected. 
Interim analyses of PROWESS-SHOCK lead to increased 
sample size because of lower than expected blinded 
mortality [23, 24]. Response adaptive trial designs are 
now used in proof-of-concept RCTs in critical care (e.g., 
l-carnitine [25]) and pivotal RCT of selepressin versus 
placebo in septic shock (https://clinicaltrials.gov/ct2/
show/NCT02508649?term=selepressin&rank=1). The 
regulatory bodies (FDA and EMEA) have accepted this 
design recently [4] (https://clinicaltrials.gov/ct2/show/
NCT02508649?term=selepressin&rank=1).
Patient safety in RCTs necessitates methods to decrease 
the risk of excess deaths due to new interventions [26]. 
Response adaptive trial design could decrease the risk 
of increased mortality only after a large sample size has 
been evaluated (27) by adjusting randomization to the 
intervention or control as the RCT progresses based on 
ongoing interim analyses. Some believe that Phase III 
mortality RCTs that stop early for efficacy overestimate 
treatment efficacy [27].
Most RCTs had secondary results that might explain 
higher mortality rates of intervention compared to 
control groups such as increased cardiovascular com-
plications (tachyarrhythmias possibly caused by the 
interventions in two RCTs (dobutamine [10]; intrave-
nous salbutamol infusion [9]), decreased cardiac output 
by excessive vasoconstriction due to NOS inhibition 
[11] or by decreased venous return secondary to high-
frequency oscillation ventilation [16]), renal toxicity 
(hetastarch increased risk of acute kidney injury [12, 18]) 
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and hypoglycemia (intensive insulin had significantly 
increased severe hypoglycemia [8]). The causes of excess 
mortality associated with human growth hormone and 
methylprednisolone [17] were not explained although 
speculations were presented [13]. Removal of TNF-α by 
TNF-α receptor was hypothesized to be potentially del-
eterious [15]. Larger Phase II proof-of-concept RCTs 
could have clarified safety risks thus modifying (e.g., 
drug dose, duration, specific safety signal monitoring) or 
avoiding pivotal Phase III RCTs.
All but one of the RCTs was preceded by prior proof-
of-principle Phase II RCTs, and another prior pivotal 
Phase III [8] RCT by the same group preceded the pivotal 
RCT. We speculate that larger, dose response adaptive 
trial design of Phase II RCTs in CCM could limit safety 
risk and increase the probability of technical success of 
Phase III RCTs.
Cardiology has improved outcomes through well-
designed, large RCTs and emphasizes a model of coop-
eration between academia and industry [28]. Cardiology 
RCTs adjusted design from lessons learned from earlier 
missteps. For example, the CAST trial [29, 30] enrolled 
patients at risk of ventricular arrhythmias and rand-
omized to the anti-arrhythmics moricizine, encainide 
or flecainide versus placebo. At the first interim analy-
sis, the DSMB recommended stopping the encainide 
and flecainide arms (pooled mortality was higher than 
placebo). Ironically, a later editorial bemoaned that two 
“potentially efficacious” drugs could be removed from 
clinical usage, not mentioning the increased mortality 
[30]. CAST catalyzed rigorous, independent monitoring 
of RCTs [31] [e.g., Academic Research Organizations in 
independent DSMBs and regulatory guidance on DSMB 
function (www.fda.gov/OHRMS/DOCKETS/98fr/01d-
0489-gdl0003.pdf)].
Our review of RCTs that found increased mortality 
in the intervention arm in CCM emphasizes caution in 
the design and monitoring of future RCTs in critically ill 
patients. Our review of Phase II proof-of-principle RCTs 
aligns with recent emphasis on Phase II RCTs [32] and 
complements other suggestions to improve chances of 
success in critical care RCTs [4].
The strengths of our analyses are wide inclusion cri-
teria, careful screening of the adult CCM RCT litera-
ture, detailed evaluation of many aspects of RCT design 
and implementation and consideration of RCT- and 
intervention-specific risks—as opposed to design risks. 
Shortcomings are that we did not have access to origi-
nal RCT data to model how the use of response adap-
tive trial design could have decreased risk of excessive 
intervention group mortality rates, we did not search 
for secondary publications that could have explained the 
causes of increased mortality in the intervention groups, 
and our findings may not apply to other fields (critically 
ill patients have increased risk of adverse events, have a 
high mortality and receive numerous interventions).
Conclusions
Some common, clinically available interventions used 
in critically ill patients increased mortality in large mul-
ticenter pivotal Phase III RCTs in adult critical care. 
We found wide ranges in sponsorship (industry or not), 
type(s) of intervention(s), use of DSMBs, presence of 
interim analyses and early stopping rules, absolute risk 
increase (ARI), and whether or not adequate prior proof-
of-principle Phase II studies were done of RCTs that 
found increased mortality rates of the intervention com-
pared to control groups. We suggest new approaches to 
decrease risk of harm in pivotal Phase III RCTs in the 
critically ill including better surrogate endpoints in POP/
Phase II RCTs to more accurately predict success in piv-
otal/Phase III RCTs, larger proof-of-principle/Phase II 
RCTs and use of response adaptive trial design in Phases 
II and III.
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